

**Date: 09th April, 2026**

To,

BSE Limited

Listing Department,

Phiroze Jeejeebhoy Towers,

Dalal Street - Fort,

Mumbai — 400 001.

Ref.: BSE Scrip Code - 539730

Subject: Outcome of Board Meeting Dated 09th April, 2026**Re: Allotment of 40,000 Equity Shares to Promoter upon conversion of Warrants into Equity Shares**

Dear Sir,

This is to inform you that Board of Directors of the Company had pursuant to the approval of Shareholders in their Extra-Ordinary General Meeting held on October 22, 2025, had allotted convertible warrants on preferential basis to Promoters on December 29, 2025.

Further, we would like to inform that the Warrant Holders have paid the balance of the consideration aggregating to Rs. 3,75,00,000/- and have applied for exercising their rights for conversion of 40,000 warrants into equivalent number of Equity Shares.

Consequently, the Board of Directors in its meeting held on April 09, 2026 has allotted 40,000 Equity Shares of face value Rs. 10/- each to the warrant holder as per following details:

Sr. No.	Name of Allottee	Category of Investor	Total number of convertible warrants allotted on December 29, 2025 (A)	Number of Equity Shares allotted upon conversion of Warrants on April 09, 2026 (B)	Number of Warrants Outstanding for Conversion (A)-(B) = (C)
1	Mrs. Daulat Nariman Medhora	Promoter	40,000	40,000	NIL





	TOTAL		40,000	40,000	NIL
--	--------------	--	--------	--------	-----

The allotment of the equity shares shall be made in dematerialized form and the equity shares so allotted shall rank pari passu with the existing Equity Shares of the Company in all respects.

The details as required under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with the SEBI Master Circular dated January 30, 2026 are enclosed as **"Annexure I"**.

The meeting commenced at 05:00 p.m. and concluded at 05:30 p.m.

Kindly take the aforesaid information on your records.

Thanking you,

FOR FREDUN PHARMACEUTICALS LIMITED

FREDUN NARIMAN MEDHORA

MANAGING DIRECTOR

DIN NO.: 01745348

Encl. : Annexure I & II



**Annexure I****Information as per Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015****Issuance of Securities:**

Sr. No.	Particulars of Securities	Details of Securities
a)	Type of securities proposed to be issued	Equity Shares upon conversion of Warrants into equivalent number of Equity Shares of Rs. 10/- each.
b)	Type of issuance	Preferential Issue in accordance with Chapter V of the SEBI ICDR Regulations 2018 and other applicable law
c)	Total number of securities proposed to be issued or the total amount for which the securities will be issued	Allotment of 40,000 Fully Paid-Up Equity Shares at an issue price of ₹ 1250/- each (including premium of ₹ 1240/- each), upon conversion for equal number of Warrants allotted at an issue price of ₹ 1250/- each upon receipt of balance amount at the rate of ₹ 937.50/- per warrant (being 75% of the issue price per warrant) aggregating to ₹ 3,75,00,000/-
In case of preferential issue, the listed entity shall disclose the following additional details to the stock exchange(s):		
i.	Name of Investors	Enclosed as “Annexure II”
ii.	Post Allotment of securities - outcome of the subscription, issue price / allotted price (in case of convertibles),	Warrants had been allotted on December 29, 2025, carrying the right to subscribe to one Equity Share per warrant on receipt of amount at the rate of Rs. 312.50/- per warrant (being 25% of the issue price per warrant.) Now, 40,000 Equity Shares have been allotted on receipt of balance amount at the rate of Rs. 937.50/- per warrant (being 75% of the issue price per warrant).
iii.	No. of Investors	01 (One)





iv.	in case of convertibles - intimation on conversion of securities or on lapse of the tenure of the instrument;	As the total consideration of the 40,000 Convertible Warrants is received, the Equity Shares are allotted pursuant to exercise of the conversion of Convertible Warrants.
v.	Any cancellation or termination of proposal for issuance of securities including reasons thereof	Not Applicable

Annexure II

Sr. No.	Name of Allottee	Category of Investor	Total number of convertible warrants allotted on December 29, 2025 (A)	Number of Equity Shares allotted upon conversion of Warrant March 25, 2026 (B)	Number of Warrants Outstanding for Conversion (A)-(B) = (C)
1	Mrs. Daulat Nariman Medhora	Promoter	40,000	40,000	NIL
	TOTAL		40,000	40,000	NIL

